|

QLS-111 Ophthalmic Solution (0.075%) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Qlaris Bio, Inc.1

Indications

  • Normal Tension Glaucoma (NTG)1
  • Open-angle Glaucoma (OAG)1
  • Non-proliferative Diabetic Retinopathy (NPDR)1
  • Diabetes1

Palo Alto, California1 trial

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Stanford University, Dept. of Ophthalmology

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.